Physician profile
Travis W Casper
NPI 1215135918
$2,375.07
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $46.06 · 2021: $524 · 2022: $769 · 2023: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $482.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $557.29 | 2021-2023 | Vraylar |
| Astrazeneca Pharmaceuticals Lp | $189.30 | 2019-2023 | Farxiga |
| Amgen INC. | $152.32 | 2019-2023 | Prolia, Evenity |
| Mallinckrodt Hospital Products INC. | $143.90 | 2021-2023 | Acthar |
| Pfizer INC. | $139.95 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.76 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $127.10 | 2019-2022 | |
| Novo Nordisk INC | $83.98 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $83.52 | 2019 | |
| Janssen Pharmaceuticals, INC | $79.72 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $79.29 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $66.67 | 2021 | |
| Opko Pharmaceuticals, LLC | $58.25 | 2019-2022 | |
| Glaxosmithkline, LLC. | $57.65 | 2019-2022 | |
| Vifor Pharma, INC. | $47.23 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $44.03 | 2021-2022 | |
| Exact Sciences Corporation | $41.71 | 2023 | Cologuard Collection Kit |
| Calliditas Therapeutics US INC. | $38.32 | 2022-2023 | Tarpeyo |
| Ultragenyx Pharmaceutical INC. | $27.86 | 2021-2022 | |
| Dexcom, INC. | $25.58 | 2022-2023 | Dexcom G6 Transmitter |
| Allergan, INC. | $22.44 | 2019 | |
| Astellas Pharma US INC | $20.50 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $19.19 | 2023 | Jynarque |
| Rhodes Pharmaceuticals L.P. | $18.54 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.40 | 2022 | |
| Covis Pharma Gmbh | $15.94 | 2022 | |
| Ironshore Pharmaceuticals INC. | $15.24 | 2020 | |
| Amarin Pharma, INC. | $14.70 | 2021 | |
| Tris Pharma INC | $12.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.89 | 2022 | |
| Lilly USA, LLC | $11.68 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.67 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Casper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.